Dr. Julie Zissimopoulos' lab focuses on understanding the economic and financial impacts of Alzheimer's disease and related dementias. The research aims to provide comprehensive and reproducible cost estimates that reflect the true burden of dementia on individuals, families, and society. By leveraging advanced modeling techniques and a multidisciplinary approach, the lab seeks to enhance the capacity for future research and inform healthcare decision-making regarding dementia care and support.

Dr. Hyungjin Eoh's lab focuses on understanding how Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB), develops resistance to antibiotics, particularly in drug-resistant forms of the disease. By investigating the metabolism of trehalose in these bacteria, the lab aims to uncover mechanisms that allow M. tuberculosis to survive antibiotic treatments, which is crucial for developing new therapies. The insights gained from this research could lead to more effective treatments for patients with drug-resistant TB, improving public health outcomes worldwide.

Dr. Paula M. Cannon's lab focuses on developing innovative gene and cell therapy strategies to create a cure for HIV. The team emphasizes making these treatments safe, effective, and accessible, especially for people living with HIV in low and middle-income countries. They work on advanced techniques involving gene editing tools, stem cell manipulation, and novel delivery methods to enhance the efficacy of HIV therapies.

Dr. Ha Youn Lee's lab at USC focuses on innovative ways to track and prevent HIV infections through advanced genetic techniques. They have developed a cutting-edge method called microdrop HIV sequencing, which helps monitor HIV trends and potential drug resistance more effectively, especially in areas with limited resources. Their research aims to improve public health response to the AIDS epidemic by providing reliable data for interventions.

Dr. Zhaoxia Qu's lab focuses on understanding how alveolar macrophages, the immune cells in the lungs, interact with pathogens and maintain lung health. They explore the role of a protein called PDLIM2 in regulating these immune responses, especially in diseases like lung cancer and pneumonia. The lab's research aims to uncover new ways to target lung diseases and improve treatment strategies.

Dr. Lucio Comai's research lab focuses on discovering new small molecule drugs for treating myotonic dystrophy type 1 (DM1), a serious genetic disorder. The lab employs innovative RNA-based screening methods to identify compounds that can effectively target and modulate disease-causing RNA, ultimately aiming to improve the lives of patients suffering from this debilitating condition. By leveraging advanced techniques and a diverse library of potential drugs, the lab is making strides in finding effective therapies where few options currently exist.

Dr. Myron Goodman's lab focuses on understanding how certain bacteria develop resistance to antibiotics, which is a serious health issue worldwide. They study an enzyme called Rum DNA polymerase that causes mutations in bacteria, helping them to quickly become resistant to drugs. By exploring how these mutations occur, the lab aims to find ways to combat antibiotic resistance.